Navidea biopharmaceuticals announces oral ruling in case involving attorney's fees

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on august 30, 2022, the district court of harris county, texas (the “court”) made an oral ruling from the bench in open court at the conclusion of the trial in case no. 2018-24442-151; capital royalty partners ii, l.p. et al. v. navidea biopharmaceuticals, inc. an
NAVB Ratings Summary
NAVB Quant Ranking